新诺威：拟发行H股并在香港联交所上市

Core Viewpoint - The company plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and competitiveness in the international market [1] Group 1 - The company aims to deepen its global strategic layout and create an international capital operation platform [1] - The issuance of H-shares is intended to promote the development of the company's pharmaceutical business [1] - The board and supervisory meetings have approved the relevant proposals, with further approval required from the shareholders' meeting and regulatory bodies [1]